BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (the “Company” or “RegeneRx”) announced today that on June 24, 2009 it received notice from NYSE Amex LLC (the “Exchange”) that the Exchange has determined to continue the listing of the Company’s common stock on the Exchange subject to the condition that, on or before October 25, 2010, the Company must comply with all applicable criteria for continued listing on the Exchange.
